Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis
Objective This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. Methods This retrospective cohort study used Optum Clinformatics® Data Mart to identify propensity score-match...
Saved in:
Main Authors: | Jashin J. Wu (Author), Ching An Wang (Author), Greeta Jobson (Author), David Davidson (Author), Samaneh Kalirai (Author), Julia Zhu (Author), Manasi Suryavanshi (Author), Mayank Mittal (Author), Vardhaman Patel (Author), Lauren Seigel (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors
by: Lana Schmidt, et al.
Published: (2023) -
Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey
by: Tina Bhutani, et al.
Published: (2024) -
Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey
by: April W. Armstrong, et al.
Published: (2024) -
Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016) -
Apremilast for lithium-associated psoriasis
by: Joohyung Youh, et al.
Published: (2022)